Head-to-head · WeighScore
Nova MD vs Omada Health
The verdict
Nova MD takes it — 66.9/100 to 55.6/100.
Nova MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Nova MD | Omada Health |
|---|---|---|
| WeighScore | 66.9/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #174 | #435 |
| Semaglutide | $175/mo (compounded) | Not disclosed |
| Tirzepatide | $225/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #174 · C
Strengths
- On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
- $125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
- $50 off first tirzepatide order shown publicly
- Explicit microdose / low-dose program for both semaglutide and tirzepatide
- Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1
Where it loses points
- Legal entity name and state of incorporation not disclosed
- Compounding pharmacy not named — only 'accredited facilities'
- LegitScript certification not confirmed (only 'Licensed US Providers' claims)
- Per-state availability not listed
- Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.